Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARCONTECH GROUP PLC AGM Information 2017

Sep 27, 2017

7493_dva_2017-09-27_60852014-75d0-471a-a065-93e57579faf5.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0198S

Arcontech Group PLC

27 September 2017

AorTech International plc

("AorTech"or the "Company")

Result of AGM

AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, is pleased to announce that at the Annual General Meeting held today, all the resolutions were duly passed.

For further information contact:

AorTech International plc 

Eddie McDaid, Chief Executive                                                                  Tel: +44 (0)7802 920869  

AorTech International plc 

Bill Brown, Chairman                                                                                     Tel: +44 (0)7730 718296 

finnCap Limited

Jonny Franklin-Adams  / Giles Rolls                                                        Tel: +44 20 7220 0500 

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA.  With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGOKODBABKDBCB